PRELIMINARY AMENDMENT ATTORNEY DOCKET NO. 1/1148-2-C2

CLAIM AMENDMENTS

IN THE CLAIMS:

- 1. (Original) Crystalline tiotropium bromide monohydrate.
- 2. (Currently Amended) Monoclinic crystalline Crystalline tiotropium bromide monohydrate according to claim 1, having an endothermic peak at 230°C± 5°C occurring during thermal analysis using DSC at a heating rate of 10K/min.
- 3. (Currently Amended) Monoclinic crystalline Crystalline tiotropium bromide monohydrate according to claim +2, having a primitive lattice type an IR spectrum comprising bands at wave numbers 3570, 3410, 3105, 1730, 1260, 1035, and 720cm⁻¹.
- 4. (Currently Amended) Monoclinic crystalline Crystalline tiotropium bromide monohydrate according to claim 2, having 4 formula units per elementary cell. an IR spectrum comprising bands at wave numbers 3570, 3410, 3105, 1730, 1260, 1035, and 720 cm⁻¹.
- 5. (Cancelled)
- 6. (Cancelled)
- 7. (Cancelled)
- 8. (Cancelled)
- 9. (Currently Amended) A process for preparing monoclinic crystalline tiotropium bromide monohydrate, the process comprising:
- (a) dissolving tiotropium bromide in water to obtain a solution;
- (b) heating the resulting solution;
- (c) adding activated charcoal to the heated solution;
- (d) removing the activated charcoal; and

PRELIMINARY AMENDMENT ATTORNEY DOCKET NO. 1/1148-2-C2

- (e) allowing the solution to slowly cool to obtain <u>monoclinic</u> crystalline tiotropium bromide monohydrate.
- 10. (Currently Amended) A process for preparing <u>monoclinic</u> crystalline tiotropium bromide monohydrate, the process comprising:
- (a) dissolving tiotropium bromide in water to obtain a solution;
- (b) heating the resulting solution to more than 50°C;
- (c) adding activated charcoal to the heated solution;
- (d) removing the activated charcoal; and
- (e) allowing the solution to slowly cool to obtain monoclinic crystalline tiotropium bromide monohydrate.
- 11. (Original) The process according to claim 10, wherein 0.4 to 1.5 kg of water are used per mole of tiotropium bromide in step (a).
- 12. (Original) The process according to claim 11, wherein 10 g to 50 g of activated charcoal per mole of tiotropium bromide is added in step (c).
- 13. (Original) The process according to claim 12, wherein the activated charcoal added in step (c) is stirred for between 5 and 60 minutes before it is removed in step (d).
- 14. (Original) The process according to claim 13, wherein step (d) is performed by filtration of the solution.
- 15. (Original) The process according to claim 14, wherein the solution of step (e) is cooled to a temperature of 20°C-25°C at a cooling rate of 1 to 10°C per 10 to 30 minutes.
- 16. (Currently Amended) A pharmaceutical composition comprising an effective therapeutic amount of crystalline tiotropium bromide monohydrate according claim I and a pharmaceutically acceptable excipient.

PRELIMINARY AMENDMENT ATTORNEY DOCKET NO. 1/1148-2-C2

- 17. (Currently Amended) A method for treatment of diseases selected from the group consisting of allergic, anti-inflammatory, respiratory, genitourinary, CNS, ophthalmic, gastrointestinal, and nausea and vomiting in which the administration of an anticholinergic agent may have a therapeutic benefit, in a patient in need of such treatment, which method comprises administering to a the patient an effective therapeutic amount of a compound according to claim 1.
- 18. (Original) The method according to claim 17, wherein the disease is asthma or COPD.
- 19. (Currently Amended) A process for preparing <u>monoclinic</u> crystalline hydrates of tiotropium bromide, the process comprising:
- (a) dissolving tiotropium bromide in water to obtain a solution;
- (b) heating the resulting solution; and
- (c) allowing the solution to slowly cool to obtain <u>monoclinic</u> crystalline hydrates of tiotropium bromide.
- 20. (Currently Amended) A process for preparing <u>monoclinic</u> crystalline hydrates of tiotropium bromide, the process comprising:
- (a) dissolving tiotropium bromide in water to obtain a solution;
- (b) heating the solution of step (a);
- (c) adding activated charcoal to the heated solution of step (b);
- (d) removing the activated charcoal from the solution of step (c); and
- (e) allowing the solution to slowly cool to obtain monoclinic crystalline hydrates of tiotropium bromide.
- 21. (Original) The process of claim 20, wherein the solution of step (a) is heated to more than 50°C.